GREEN LIFESCIENCE CO., LTD.
Financials
Valuation Metrics
GREEN LIFESCIENCE CO., LTD.'s Market Cap is ₩466B. At end of 2025 it was ₩580B. Ranked #1786 of 2,436 in KR market (top 73%), #1087 of 1,649 on KOSDAQ (top 66%), #196 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 84%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 46.60B KRW | KR#1,786/2,436 Sec#196/234 |
| Revenue | 51.02B KRW | KR#1,763/2,436 Sec#121/234 |
| Net Income | 3.01B KRW | KR#1,265/2,436 Sec#87/234 |
| Total Assets | 56.01B KRW | KR#2,132/2,436 Sec#189/234 |
| Net Assets | 40.04B KRW | KR#2,023/2,436 Sec#178/234 |
| Employees | 65 | KR#1,909/2,436 Sec#166/234 |
| Value | ||
| P/E | 15.48x | KR#1,003/2,436 Sec#63/234 |
| P/B | 1.16x | KR#1,612/2,436 Sec#109/234 |
| P/S | 0.91x | KR#1,329/2,436 Sec#74/234 |
| EV/EBITDA | 21.46x | KR#1,049/2,436 Sec#61/234 |
| FCF Yield | -1.06% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | 7.52% | KR#740/2,436 Sec#49/234 |
| ROA | 5.37% | KR#607/2,436 Sec#47/234 |
| Op. Margin | 3.77% | KR#1,097/2,436 Sec#84/234 |
| Revenue Growth | 219.16% | KR#60/2,436 Sec#9/234 |
| Earnings Growth | -56.61% | KR#1,233/2,436 Sec#79/234 |
| Financial Health | ||
| Debt Ratio | 139.89% | KR#1,032/2,436 Sec#119/234 |
| Total Debt | 4.80B KRW | KR#1,791/2,436 Sec#171/234 |
| FCF | -495.7M KRW | KR#1,255/2,436 Sec#95/234 |
| Cash | 10.12B KRW | KR#1,665/2,436 Sec#133/234 |
| Current Ratio | 2.17x | KR#863/2,436 Sec#100/234 |
| Net Debt/EBITDA | -2.76x | KR#218/2,436 Sec#10/234 |
| Dividend | ||
| Div. Growth | 0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | -12.41% | KR#1,040/2,436 Sec#78/234 |
| 1M Return | 22.76% | KR#106/2,436 Sec#5/234 |
| From 52W High | -49.24% | KR#1,152/2,436 Sec#99/234 |
| 1Y MDD | -57.31% | KR#1,266/2,436 Sec#104/234 |
| Trading | ||
| Volume | 156,019 shares | KR#700/2,436 Sec#68/234 |
| Foreign Own. | 4.79% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 151 KRW | KR#1,287/2,436 Sec#91/234 |
| BPS | 2,019 KRW | KR#2,019/2,436 Sec#166/234 |
Company Info
Green Life Science, established in 2005 and headquartered in Yeosu-si, Jeollanam-do, is a specialized manufacturer of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates, listed on the KOSDAQ market in 2009. The company pioneered the development of EDP-CL, a piperacillin-based antibiotic intermediate, in Korea, supplying it to global pharmaceutical companies, and its synthesis plant was the first in Korea to receive U.S. FDA approval. It produces various APIs and raw material intermediates, including DSC for HIV treatment and antibiotic intermediate AM19, while maintaining a quality management system compliant with cGMP standards.